Target- |
Mechanism- |
|
|
|
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
Mechanism- |
Active Org.- |
|
Active Indication- |
|
Drug Highest PhasePending |
First Approval Ctry. / Loc.- |
First Approval Date- |
Dose Escalation Safety Study of MM-10-001
The purpose of this study is to evaluate the safety of increasing doses of MM-10-001 and to determine the dose of MM-10-001 that enhances the immune system in normal healthy subjects.
100 Clinical Results associated with GlycaNova Norge AS
0 Patents (Medical) associated with GlycaNova Norge AS
100 Deals associated with GlycaNova Norge AS
100 Translational Medicine associated with GlycaNova Norge AS